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Targeting glycolysis by 3-bromopyruvate
improves tamoxifen cytotoxicity of breast
cancer cell lines
Yasmin M. Attia1, Hanan S. EL-Abhar2, Mahmoud M. Al Marzabani1ˆ and Samia A. Shouman1*
Abstract
Background: Tamoxifen is the standard endocrine therapy for ER+ breast cancer; however, many women still relapse
after long-term therapy. 3-Bromopyruvate, a glycolytic inhibitor, has shown high selective anti-tumor activity in vitro, and
in vivo. The aim of this study was to evaluate the possible augmentation of the effect of tamoxifen via reprograming
cancer cell metabolism using 3-bromopyruvate.
Methods: An in vitro screening of antitumor activity as well as the apoptotic, anti-metastatic, and anti-angiogenic
potentials of the combination therapy were carried out using different techniques on breast cancer cell lines
MCF7and T47D. In addition the antitumor effect of the combined therapy was done on mice bearing tumor.
Results: Our results showed modulation in apoptosis, angiogenesis and metastatic potential by either drug
alone; however, their combination has surpassed that of the individual one. Combination regimen enhanced
activated caspases-3, 7 and 9, as well as oxidative stress, signified by increased malondialdehyde and decreased
glutathione level. Additionally, the angiogenesis and metastasis markers, including hypoxia inducing factor-1α,
vascular endothelia growth factor, and metaloproteinases-2 and 9 were decreased after using the combination
regimen. These results were further confirmed by the in vivo study, which depicted a decrease in the tumor
volume and angiogenesis and an increase in oxidative stress as well.
Conclusion: 3-bromopyruvate could be a valuable compound when added with tamoxifen in breast cancer treatment.
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Background
Breast cancer was estimated one of the most commonly
diagnosed cancers worldwide among women (11.9 %). It
is the most common cause of cancer death and the most
frequently diagnosed cancer in 140 out of 184 countries
worldwide [1] including Egypt, where there were an esti-
mated 49.5 cases of breast cancer per 100,000 adults in
2012 [2]. Among the different molecular subtypes of
breast cancer, estrogen (ER) positive comprises ~70 % of
all breast cancers cases [3].
Tamoxifen (TAM), a synthetic nonsteroidal anti-
estrogen, has been used widely as the gold standard
endocrine therapy for most women with ERα + breast
cancer. Five years of TAM treatment reduced the risk of
relapse of 10 years by 37 % in females aged 50-59 years,
and by 54 % in females aged 60–69 years [4]. The anti-
proliferative effects of TAM may relate to its antiestro-
genic effect via binding competitively to estrogen
receptor, thereby blocking the mitogenic effect of estro-
gens [5]. TAM also induces apoptosis of cancer cell
through several distinct mechanisms including its inhib-
ition of protein kinase C and its binding to calmodulin,
a protein that plays a role in DNA synthesis [6]. Al-
though TAM is an extremely effective treatment for mil-
lions of patients with breast cancer, a significant
proportion, as much as 30 % of women still relapse dur-
ing or after long-term therapy [7]. Besides, some patients
display de novo or acquired resistance [5].
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The competency to increase response and reduce che-
moresistance of cancer therapeutics via the use of the
combination therapy as well uncovering underlying
mechanisms of chemoresistance would be a significant
advantage for cancer patients. The development of a
combination therapy that increases the efficacy of TAM
has been investigated in several studies, using vitamin E
[8] and green tea [9]. Moreover, mounting evidence sup-
ports, that reprogramming of cellular metabolism in
cancer cells is linked to failure of treatment, and drug
resistance in cancer therapy [10].
The glycolysis pathway is one of the main characteris-
tics of tumor cells, which increases dramatically with
malignancy [11]. Such increased aerobic glycolysis has
been observed in a variety of cancer types; hence, target-
ing this pathway in cancer cells provides a biochemical
basis for developing new chemotherapeutic strategies. 3-
Bromopyruvate (3-BP) is an inhibitor of the glycolysis
process that has shown remarkable anti-tumor efficacy,
documented by both in vitro [12] and in vivo [13] stud-
ies. 3-BP mediates its effect by causing cell cycle arrest,
inducing apoptosis and inhibiting angiogenesis activity,
which closely related to glycolysis inhibition [14]. There-
fore, we hypothesized that the use of glycolytic inhibitor
(3 BP) could increase TAM efficacy on MCF-7 and
T47D cell lines, as well as on mice -bearing Ehrlich solid




Tamoxifen (TAM) and 3-BP were obtained from Sigma
Aldrich Chemical Co. (St. Louis, MO, USA). Each vial of
TAM contains one gm white powder. It was dissolved in
DMSO to yield 50 μM then serially diluted in RPMI-
1640 medium immediately before use to yield a concen-
tration range of 10–50 μM. 3-Bromopyruvate (3-BP) was
obtained in a vial containing 10 g white powder. It was
dissolved in saline to yield 50 μM then serially diluted in
RPMI-1640 supplemented medium immediately before
use to yield a concentration range of 10–50 μM.
Chemicals
RPMI-1640 Medium, fetal bovine serum, dimethylsulf-
oxide (DMSO), Ellman’s reagent [5,5-Dithio-bis-(2-nitro
benzoic acid)], β-mercaptoethanol, reduced glutathione,
sodium dodecyl sulfate (SDS), sodium bicarbonate,
1,1.3,3-tetramethoxypropane, trichloroacetic acid (TCA)
and thiobarbituric acid were all purchased from Sigma
Aldrich Chemical Co. (St. Louis, MO, USA). Triton X-
100 was procured from MP Biochemical (Santa Ana,
California, USA). All other chemicals and reagents were
from standard analytical grade.
Cell lines and animals
Cell lines
Breast carcinoma estrogen receptor positive (ER+) cell
lines MCF-7 and T47D were used in this study. They
were obtained frozen in liquid nitrogen (−180 °C) from
the American Type Culture Collection Organization
(USA). The tumor cell lines were maintained by serial
sub-culturing at the National Cancer Institute, Cairo,
Egypt. They were cultured in a humidified incubator at
37 °C and 5 % CO2 in RPMI-1640 medium supple-
mented with 10 % fetal bovine serum, 100 U/ml penicil-
lin, 100 mg/ml streptomycin, and 3 mM/l glutamine.
The cells were trypsinized every 3 days.
Animals
24 Female Swiss albino mice, weighing 22–25 g, were
obtained from the National Cancer Institute, Cairo,
Egypt. All of the animal handling and study procedures
were approved by the research ethics committee of Fac-
ulty of Pharmacy, Cairo University, Cairo, Egypt (Permit
Number: PT 661), and was conducted with the “Guide
for the Care and Use of Laboratory Animals”. Animals
were kept under suitable laboratory conditions of
temperature and humidity. They were provided with
standard chow and water and housed in plastic cages.
In-vitro parameters
Cytotoxicity assay
To study the antitumor activity of TAM, 3BP, and their
combination on breast cancer cells, sulphorhodamine-B
(SRB) method as described by Skehan et al. [15] was
used. In brief; cells were seeded at a density of 3 × 103
cells/well in 96-well microtiter plates. They were left to
attach for 24 h before incubation with drugs. Next, cells
were treated with different concentrations of TAM, 3BP
(10, 20, 30, 40 and 50 μM). The combination regimens
was designed using IC50 of TAM with different concen-
trations (10, 20, 30, 40, 50 μM) of 3BP. For each concen-
tration, three wells were used and incubation was
continued for 48 h. A control wells containing, vehicles
DMSO (1 % v/v) for TAM, and media for 3-BP were
used. At the end of incubation, cells were fixed with 20
% trichloroacetic acid (TCA), stained with 0.4 % SRB
dye. The optical density (O.D.) of each well was mea-
sured spectrophotometrically at 570 nm using ELISA
microplate reader (TECAN sunrise™, Germany).
The mean survival fraction at each drug concentra-
tion was calculated as follows: O.D. of the treated
cells/O.D. of the control cells. The IC50 (concentra-
tion that produce 50 % of cell growth inhibition)
value of each drug was calculated using sigmoidal
dose response curve-fitting models (Graph Pad Prizm
software, version 5).
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In all the following mechanistic experiments, we used
the first concentration of 3BP that produced significant
decrease of survival with IC50 of TAM in both cell lines.
Therefore, we used in MCF-7, 20 μM of TAM, 3BP and
their combination, while in T47D it was 30 μM of 3-BP
and 20 μM TAM and their combination.
Real time polymerase chain reaction (qPCR)
In order to study the effect of different treatments on
angiogenesis, metastasis and apoptosis, the gene expres-
sion levels of mRNA of hexokinase (HK2), hypoxia indu-
cing factor (HIF1-α), and metalloproteinase (MMP 2
and 9) as well as caspase 9 were assessed using q PCR.
The total cellular RNA was extracted following the
protocol of the RNeasy Mini Kit (Qiagen, Valencia, CA).
Reverse transcription was completed using High capacity
cDNA archive kit (Applied Biosystem, California, USA).
Real time PCR of GAPDH, caspase 9, HK2, HIF1-α, and
(MMP 2 and 9) were performed in triplicate on an ABI
7500 Fast Real-Time PCR System using the GoTaq PCR
master mix (Promega, Madison, U.S.A). Fast amplifica-
tion parameters were as follows: one cycle at 95 °C for
10 min, followed by 40 cycles at 95 °C for 15 s, and 60 °C
for 1 min. All primers used in this study were purchased
from Invitrogen (California, USA) (Table 1). Quantitative
analysis of data was performed by using theΔΔ Ct method
[16]. Values were normalized to GAPDH and were
expressed as relative expression levels.
Assay of caspase-3 activity
To confirm our data different techniques as ELISA, gelatin
zymography and western method were used
Caspase 3, the executioner caspase, was assessed
spectrophotometrically at 450 nm in cell lysate using
ELISA kit (Invitrogen, Carlsbad, CA, USA) following
the manufacturer’s instructions [17]. Cells were cul-
tured in 75 cm3 flasks, left till 70–80 % confluent,
cells were treated with the different drug for 48 h.
The treated and control cells were lysed in a RIPA
lysis buffer containing protease inhibitors. Each con-
centration repeated two times and the experiment
was carried out three independent times. The activity
was calculated relative to the corresponding protein
content.
Protein concentration assay
Protein concentrations were measured in the medium
and cell lysate by the method described previously by
Bradford [18] using kit (Pierce, Rockford, IL, USA). The
method depends on the binding of Comassie Brilliant
Blue G-250 dye with protein and forming a complex
which can be measured spectrophotometrically at
595 nm then the concentration was determined using a
standard calibration curve.
Assay of VEGF-A level
VEGF was determined in cell culture medium using
eBioscience (San Diego, CA, USA) ELISA kit. MCF-7
and T47D cells were plated in 6 well plate with 5*104 /
well. After treatment with drugs, the medium was aspi-
rated, centrifuged at 10,000 rpm for 10 min at 4 °C to
remove any dead cells. The clear supernatant was used
for assay following the manufacturer’s instructions [19].
Determination of matrix metalloproteinases (MMP)-2 and
9 activities by gelatin zymography
Cells were seeded in 75 cm3 flasks, left for 24 h, and
then treated with TAM, 3 BP, or their combination for
48 h. Cells were harvested and protein concentration of
each sample was determined by Bradford method [18].
Briefly, 20 μg protein /lane was prepared in a non-
reducing loading buffer consisting of 63 mM Tris–HCl
pH 6.8, 10 % glycerol (v/v), 2 % sodium dodecyl sulphate
(SDS) (w/v), 0.0025 % bromophenol blue (w/v), and elec-
trophoresed on 10 % SDS-polyacrylamide gels contain-
ing 0.1 % gelatin. After electrophoresis, SDS was
removed from gels by incubation with renaturation buf-
fer (2.7 % TritonX-100) for 1 h, then incubated for 24 h
at 37 °C in developing buffer (50 mM Tris–HCl, pH 7.5,
0.2 M NaCl, Triton-X 5 ml and 5 mM CaCl2), stained
with coomassie brilliant blue and destained using
destaining solution (10 % methanol, 5 % acetic acid).
Enzyme-digested regions were observed as clear bands
against a dark blue background. Gels were scanned using
image Scanner III LabScan6.0 and the subsequent. In





HIF-1 α 5′- CAAGAACCTACTGCTA ATGC-3 5-TTATGTATGTGGGTAGGAGATG-3
MMP-2 5-TGCCCAAGAATAGATGCTGAC-3 5-GAAAGGAGAAGAGCCTGAAGTG-3
MMP-9 5- CTTCT GCCCGGACCAAGGATAC-3 5-TTCAGGGCGAGGACCATAGAGG-3
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order to determine mean intensity of each band (mean
pixel), the band densities were measured with Scion
Image Beta 4.0.2 (Scion Co., Frederick, MD, U.S.A.) soft-
ware. For the quantitative analysis, each of the bands
was compared with β-Actin taken as a control.
Western blot
Cells were washed twice with PBS and lysed in cell lysis
buffer (150 mM NaCl,10 mM Tris, 0.2 %TritonX-100,
0.3 %nonylphenoxy-polyethoxyethanol-40, 0.2 %mM
Na3VO4, protease inhibitor cocktail). The cell lysates
were centrifuged and the protein concentration was
measured as previously mentioned. Each sample was
separated by electrophoresis using 8 % SDS-PAGE gel
and analyzed by Western blotting using the following
antibodies: primary rabbit anti-human MMP-9 (Novus-
bio, Colorado, USA), and β-HK2 (Cell signaling, Beverly,
Massachusetts, USA), as well as primary mouse anti-
human HIF-1α (eBioscience, CA, USA), MMP-2 (Invi-
trogen, CA, USA), caspase-7 (Novusbio, Colorado,
USA), and β-Actin (Sigma-Aldrich Chemical Co., USA).
Horseradish peroxidase linked to the corresponding sec-
ondary antibody was used at 1:5000 dilution. The mem-
brane was visualized by exposure to Kodak XAR film.
For the quantitative analysis, the mean intensity of each
band (mean pixel), was compared with β-Actin band
using with Scion Image Beta 4.0.2 (Scion Co., MD,
U.S.A.) software.
Oxidative stress markers (reduced glutathione and lipid
peroxide)
In order to explore the role of oxidative stress in drug -
induced cytotoxicity, levels of lipid peroxide and reduced
glutathione (rGSH were determined. Glutathione con-
tent was determined according to the method of Ellman
[20]. The treated and control cells were collected in
phosphate buffer, protein was precipitated with
trichloroacetic acid (TCA) and centrifuged. The super-
natant was treated with Ellman’s reagent, the developed
color was measured spectrophotometrically at 405 nm
using a spectrophotometer (Spectronic, Milton Ray Co.,
USA). Lipid peroxidation products were quantified by
measuring malonaldialdehyde (MDA) level to the
method described by Draper and Hadley [21]. Treated
and control cells were mixed well with of 20 % (w/v)
trichloroacetic acid (TCA) containing 0.8 % (w/v) thio-
barbituric acid (TBA), incubated in a boiling water bath
for 1 h. The absorbance of the supernatant was deter-
mined at 535 nm using a spectrophotometer (Spectro-
nic, Milton Ray Co., USA). The concentrations were
calculated using MDA standard calibration curve by pre-
paring a serial dilutions of 1,1,3,3- tetraethoxypropane.
In-vivo parameters
Assessment of the antitumor activity in mice-bearing solid
Ehrlich carcinoma (EAC)
Ehrlich carcinoma (EAC)-cells (2 × 106) were trans-
planted subcutaneously in the right thigh of the lower
limb mice. 24 Mice with a palpable tumor mass (ap-
proximate 100 mm3), which developed within 7 days
after implementation, were divided randomly and blindly
into 4 groups each 6 animals. Group one injected i.p
with 5 mg/kg TAM, group two injected with 3-BP
(10 mg/kg), group three treated with their combination
and control group received saline. Treatment continued
twice/weekly for 3 weeks. The change in tumor volume
was measured using venire caliber and calculated by the
following formula according to Osman et al. [22].
Tumor volume mm3 ¼ 0:52 A2  B
Where A and B denote the minor and major tumor axis,
respectively.
Reduced glutathione (rGSH) and MDA contents in solid
tumor tissue
Twenty four hours after the last treatment, animals were
anesthetized with sodium pentobarbital 100 mg/kg i.p,
Fig. 1 Cytotoxicity of TAM and 3-BP on MCF7 and T47D breast cancer cell lines after 48 h. Surviving fraction and I.C50 of MCF-7 (a) and T47D (b),
cells treated with TAM and 3-BP after 48 h. Results are expressed as the mean ± SD of 5 independent experiments performed in triplicate. * Significantly
different from control at P < 0.05
Attia et al. BMC Cancer  (2015) 15:838 Page 4 of 14
then cervical dislocation was done with high degree of
proficiency to anesthetized animals according to Euthan-
asia guidelines. Tumors were quickly excised, washed
with saline, blotted with a piece of filter paper, and
homogenized using a Branson sonifier (250, VWR Sci-
entific, Danbury, Connecticut, USA). The homoge-
nates were centrifuged at 800 g for 5 min at 4 C° to
separate the nuclear debris, then supernatant was
again centrifuged at 10,500 g for 20 min at 4 C°.
Levels of glutathione and MDA were determined as
previously described.
Immunohistochemical staining (IHC) of VEGF
Representative tissue samples were fixed in 10 % neutral
phosphate-buffered formalin, embedded in paraffin, and
sectioned at 5 μm thickness. Sections were incubated
Fig. 2 Effect of addition of 3-BP on the cytotoxicity of 20 μM TAM on MCF-7 and T47D cell lines. Cells were treated with different concentrations
of 3-BP and 20 μM TAM (a, b, respectively). Results are expressed as the mean ± SD of 5 independent experiments performed in triplicate. The
statistical significance of the results was analyzed by one way ANOVA using Tukey multiple comparison test using one way analysis of variance
(ANOVA). “a” Significantly different from its control and “b” from 20 μM TAM at P < 0.05
Fig. 3 Oxidative stress markers following treatment with TAM, 3-BP and their combination. Effect of different regimen on lipid peroxidation in MCF-7
(a) and T47D (b). Figure (c) and (d) show the content of reduced glutathione (rGSH) in MCF-7 and T47D, respectively after 48 h treatment with 3-BP, TAM
and their combination. Results are expressed as means ± SD of 2 independent experiments performed in duplicates. Statistical significance of results was
analyzed by one way ANOVA using Tukey’s multiple comparison test. “a” Significantly different from control, “b” from 3-BP and “c” from TAM at P≤ 0.05. ♦
means synergistic and * means potentiating interaction when TAM and 3-BP where combined using factorial design
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with monoclonal mouse anti-VEGF antibody (Sigma Al-
drich Chemical Co., USA) as a primary antibody at a di-
lution of 1:150 overnight at 4 °C then rinsed three times.
Sections were incubated with polymer horseradish per-
oxidase HRP secondary antibody (Sigma Aldrich Chem-
ical Co., USA) for 1 h. Immuno-reactivity was detected
by the standard avidin–biotin immunoperoxidase
method. Counterstaining with Meyer’s hematoxylin was
then performed for 5 min. Thereafter, they were evalu-
ated under light microscope (Olympus, Japan) and ana-
lyzed with Scion Image Beta 4.0.2 (Scion Co., Frederick,
MD, U.S.A.) software.
Fig. 4 Effect of 48 h treatment with 3-BP, TAM and their combination on apoptosis markers. Caspase-3 activity in MCF-7 cells (a) and T47D cells
(b). Expression of Caspase −9 gene using qPCR in MCF-7 (c) and T47D (d). Caspase 7 protein level was done by western in MCF-7 (e) and T47D
(f). Results are expressed as means ± SD of 2 independent experiments performed in duplicates. Significance was determined with one way ANOVA using
Tukey’s multiple comparison test. “a” Significantly different from control, “b” rom 3-BP and “c” from TAM at P≤ 0.05. ♦ means synergistic and * potentiation
interaction when TAM and 3-BP where combined using factorial design
Fig. 5 Levels of VEGF in breast cancer cell lines following treatment with 3-BP, TAM and their combination. Effect of TAM, 3-BP and their combination on
level of VEGF-A in the MCF-7 (a) and T47D (b) cells media. Results are expressed as means ± SD of 2 independent experiments performed in duplicates.
Significance was determined with one way ANOVA using Tukey’s multiple comparison test. “a” Significantly different from control, “b” rom 3-BP and“c” from
TAM at P≤ 0.05. ♦ means synergistic and * potentiation interaction when TAM and 3-BP where combined using factorial design
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Statistical analysis
All data were expressed as mean ± S.D. The difference
between the treated samples and the untreated controls
was analyzed by one way ANOVA followed by Tukey mul-
tiple comparison test in which p < 0.05 was considered as
significant. To test for interaction between individual
treatments when given in combination, a factorial design
test is used. All statistical analysis was performed using
GraphPad In Stat, version 5.0 (GraphPad, San Diego, Cali-
fornia, USA). Compusyn software was used to determine
the interaction between the two drugs in the combination.
Statistical significance was set at p < 0.05.
Results
In vitro
3-BP enhances cytotoxicity of TAM on MCF7 and T47D cells
Figure 1 showed that treatment of MCF7 [A] and T47D
[B] cells with various concentrations (10–50 μM) of
TAM or 3-BP for 48 h caused a concentration
dependent decrease in cell survival. The IC50 of TAM
was 20 and 23 μM, while that of 3-BP was 36 and
33 μM in MCF7 and T47D, respectively. Addition of
20 μM of 3BP increased significantly cytotoxicity of
20 μM TAM in MCF-7 cells, while, T47D cells required
30 μM of 3BP to produce significant increase in cell
death compared to TAM alone (Fig. 2a and b).
3-BP synergizes oxidative stress and activates apoptotic
machinery of TAM on MCF7 and T47D cells
Both TAM and 3-BP increased significantly the MDA
level (Fig. 3a, b), but leveled off the rGSH content
(Fig. 3c, d) significantly in the two breast cancer cell
lines. The addition of 3-BP to TAM caused synergistic
effect on the oxidative stress (lipid peroxidation) in both
cell lines and a synergistic effect on glutathione content
in MCF-7 but in T47D cells, the interaction was potenti-
ation. Treatment of breast cell lines with TAM, 3-BP
and their combination has switched on the apoptotic ac-
tivity assessed as caspases 3, 7 and 9. The effect of the
different treatment regimens had activated caspase-3
(Fig. 4a, b), with the 3-BP showing the least effect and
the combined treatment showing the highest action with
synergistic interaction. The same pattern was mirrored
in the 2 cell lines. The same effect was observed on the
expression of caspase-9 (Fig. 4c, d) but the interaction
was synergistic on MCF-7 and potentiation on T47D
Fig. 6 Effect of TAM, 3-BP and their combination on the level HIF-1α. The expression level of HIF-1α in MCF-7 and T47D cells (a, b). The effect of
different treatments on the protein level (c, d). Results are expressed as means ± SD of 2 independent experiments performed in duplicates for qPCR
experiment. The results for western blot are expressed as means ± SD of 3 independent experiments. Significance was done by one way ANOVA using
Tukey’s multiple comparison test. “a” Significantly different from control, “b” from 3-BP and “c” from TAM at P≤ 0.05. ♦ means synergistic and * potentiation
interaction when TAM and 3-BP where combined using factorial design
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cells. Additionally, the three treatments succeeded to
cleave caspase-7 as shown in (Fig. 4e, f ) using western
blot.
Combined treatment of TAM and 3BP inhibits VEGF-A, HIF-1α,
HK-2 and metalloproteinases 2, 9
As depicted in Fig. 5a, b, VEGF-A activity was inhibited
by the combined regimen showing the best effect with
synergistic interaction on MCF-7 and potentiating inter-
action on T47D. Regarding the effect on the HIF-1α ex-
pression (Fig. 6a, b), TAM and/or 3-BP showed the same
previous pattern with a more pronounced effect on the
MCF-7 cell line. Nevertheless, these results were not
reflected exactly on the HIF-1α protein content assessed
by the western blot technique (Fig. 6c, d) as the inter-
action was synergistic in the expression level but it was
potentiation one in protein level. The expression and the
protein level of HK2 were presented in Fig. 7a-d. As ex-
pected the inhibitory effect of 3-BP on the HK2 sur-
passed that of TAM alone in the 2 breast cell lines
studied herein. Despite the combination effect added a
further inhibition in the HK2 expression as compared to
the 3-BP alone with synergistic interaction, however, this
effect was lost in the protein verification (Fig. 7c, d).
TAM increased MMP 2 and 9. Surprisingly, 3-BP caused
a sharp decline in the MMPs in the two breast cell lines
to reach even a lower level below the untreated control
group. The combination regimen succeeded to lower the
TAM effect on the secreted MMP 2 and 9 (Fig. 8a, b);
the same pattern was observed by the q-PCR technique
(Fig. 8c, d) and the Western blot assay (Fig. 9a-d) with
antagonistic interaction.
In vivo
3-BP enhances the antitumor effect, increases oxidative
stress and inhibits VEGF of TAM in vivo
The results of in vitro are also documented in vivo, the
volume of Ehrlich tumor was decreased by 52 and 37 %
in individually treated TAM or 3-BP respectively; how-
ever, the combination regimen caused a further decrease
reaching 80 % as compared to the control untreated
group (Fig. 10). An increase in MDA and decrease rGSH
with synergistic interaction in the combination using
factorial design was also observed (Fig. 11a, b). More-
over, as presented in Fig. 12a-d, all the treatment regi-
mens lowered the level of VEGF expression to different
extent when compared to the control group. Moreover,
Fig. 7 Effect of TAM, 3-BP and their combination on the level Hexokinaes-2 (HK-2). HK-2 gene expression of 3-BP, TAM and the combination regimen
(a, b). The effect of different treatments on the HK-2 protein level. (c, d). Results are expressed as means ± SD of 2 independent experiments performed
in duplicates for qPCR experiment and for western blot the results are expressed as means ± SD of 3 independent experiments. Significance was done
by one way ANOVA using Tukey’s multiple comparison test. “a” Significantly different from control, “b” from 3-BP and “c” from TAM at P≤ 0.05. ♦ means
synergistic and * potentiation interaction when TAM and 3-BP where combined using factorial design
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in the combination treated group the expression was
even less than either treatment alone.
Discussion
Breast cancer (BC) is the most commonly diagnosed
cancer and the leading cause of cancer-related deaths
among females worldwide [1]. ER status is the most im-
portant and primary determinant of treatment options
through targeting ER functions by TAM or synthesis by
aromatase inhibitors [23]. TAM is the first endocrine
therapy; it acts as an antagonist for estrogen receptors in
pre and postmenopausal breast cancer by controlling the
binding of estradiol to the ER and forms a TAM-ER
complex which then binds to DNA. This leads to the
failure of transcriptional activation and growth inhibition
in estrogen-dependent cells [5].
Our data showed either TAM or 3BP alone or in com-
bination inhibited the survival of breast cancer cell lines
as well as in mice bearing EAC tumor. The combination
regimen enhanced significantly the growth inhibition
both in vitro and in vivo. TAM was reported as effective
anticancer against many types of cancer other than
breast including hepatocellular carcinoma, lung cancer
[24, 25] and colon cancer [26] cell lines. The in vitro
findings were further elucidated in an in vivo model of
EAC bearing mice. The present study showed that TAM
and 3-BP can reduce the volume of solid tumor in mice
bearing tumor. Several studies have also documented the
antitumor effect of TAM and 3BP in vivo [13, 50]. More-
over, the combination of both drugs reduced the tumor
significantly from TAM or 3-BP treated groups. It in-
creases the level of p53 which is responsible for activa-
tion of many genes to induce apoptosis [27]. In addition,
TAM causes induction of c-Myc, activation of members
of mitogen-activated protein kinase (MAPK) family as
well as increased accumulation of ceramide which serves
as a second messenger in cell survival [28]. Moreover, 3-
Bromopyruvate (3-BP) is a promising glycolytic inhibitor,
in this study; it increases significantly the cytotoxicity of
TAM. 3BP was found to have anticancer effects on many
Fig. 8 Effect of TAM, 3-BP and their combination on the extracellular level and the expression of Metastasis markers. After adding 3-BP to TAM
succeeded to decrease the extracellular level of MMP-2 and 9 using gelatin zymography in MCF-7 cells (a) and T47D (b) cells. The analysis was
done by image software. The effect of this combination on the secreted MMPs was reflected on their genes expression using qPCR in MCF-7
(c) and T47D (d). Results are expressed as means ± SD of 2 independent experiments for zymography but for qPCR results are expressed as
means ± SD of 2 independent experiments performed in duplicates. Significance was determined with one way ANOVA using Tukey’s multiple
comparison test.“a” Significantly different from control, “b” from 3-BP and “c” from TAM at P ≤ 0.05. ♦Significant interaction (antagonism) when TAM
and 3-BP where combined using factorial design
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types of cancer including; leukemia [29], breast cancer cell
line and hepatocellular carcinoma [30]. This may be related
to the ability of 3BP to act as multi-targeted inhibitor of
glycolytic pathway and mitochondria. It covalently binds to
the glycolytic enzymes; hexokinase-2 [31], Glyceraldehyde-
3-phosphate dehydrogenase [32] and mitochondrial; suc-
cinate dehydrogenase [33], in addition, to the endoplasmic
reticulum [27] and the lysosomes [32] resulting in severe
depletion in ATP and cancer death [34].
The antitumor effects of TAM observed in this study,
was accompanied by significant increase in ROS and ac-
tivation of different caspases at both m RNA and protein
levels resulting in induction of apoptosis. Additionally,
both the individual drug and combination treated mice
showed increase in the oxidative stress markers in vivo.
TAM increases mitochondria oxidative stress markers in
vitro and in vivo [35] and induces collapse of mitochon-
drial transmembrane potential [36] that triggers release
of cytochrome c from mitochondria which activates pro-
caspase-9,7 and 3 leading to apoptosis [37]. In addition,
Fig. 9 Effect of TAM, 3-BP and their combination on the protein level of the Metastasis markers. The results of zymography and qPCR were confirmed also
by western technique for MMP-2 and 9 in the cells of MCF-7 (a, c) and T47D (b, d). Results are expressed as means ± SD of 2 independent experiments
western. The analysis was done by image software. Significance was determined with one way ANOVA using Tukey’s multiple comparison
test.“a” Significantly different from control, “b” from 3-BP and “c” from TAM at P≤ 0.05. ♦Significant interaction (antagonism) when TAM and 3-BP where
combined using factorial design
Fig. 10 Tumor volume of solid Erlich carcinoma-bearing mice after
treatment with 3-BP, TAM or their combination. The tumor volume
was markedly reduced in mice treated 3-BP (10 mg/kg), TAM (5 mg/kg);
however the best result was observed in group treated with
combination of both drugs. Results are expressed as means ± SD
of tumor volume from 6 mice. Results are analyzed by one way
ANOVA using Tukey’s multiple comparison test. “a” Significantly
different from control,“b” from 3-BP and “c” from TAM at P < 0.05.
♦Significant interaction when TAM and 3-BP where combined
using factorial design
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oxidative stress increases intracellular Ca2+concentrations
leading to leak in the plasma membrane [38] and activation
of endonucleases which degrade DNA and, ultimately, con-
tribute to cell death [39].
In our study the apoptotic effect of TAM is enhanced
upon its combination with 3BP in both breast cancer cell
lines compared to each drug individually. 3-
Bromopyruvate, as a member of the mitocans, it exerts its
pro-apoptotic mechanism on cells via disruption the
mitochondria membrane potential causing the generation
of mitochondrial ROS [40]. One of the major consequences
of the disruption of the mitochondrial membrane potential
by reactive oxygen species (ROS) is the release of the cyto-
chrome c [41] in the cytosol and initiation of the caspase
cascade by activating pro-caspase-9. Mature caspase-9 then
activates the executioner caspases including caspase-
3which is a point of no return in apoptosis. Caspase-3 then
cleaves a variety of vital biological macromolecules [42].
Fig. 11 Effect of TAM, 3-BP and their combination on oxidative stress in vivo. a shows the level of the Glutathione level and b shows the lipid
peroxidation following treatment with 3-BP and TAM and their combination. Results are expressed as means ± SD of tumor volume from 6 mice.
Results are analyzed by one way ANOVA using Tukey’s multiple comparison test. “a” Significantly different from control,“b” significantly different from 3-BP
and “c”significantly different from TAM at P< 0.05. ♦Significant interaction when TAM and 3-BP where combined using factorial design
Fig. 12 VEGF expression using immunohistochemsitry. a: Paraffin section photograph of mouse solid tumor (control group) showing the increased
VEGF expression in most tumor cells, the large capillaries and hyperchromatic cells were present (4/5 of the field). b: Paraffin section photograph of
mouse solid tumor (group treated with 10 mg/kg3-BP) showing the VEGF expression in most tumor cells absent the apoptotic cells (3/5 of the field).
c: Paraffin section photograph of mouse solid tumor (group treated with 5 mg/kg) showing the VEGF expression in some tumor cells, absent in mitotic
and apoptotic cell, large conjugated blood vessels were observed. (1/5 of the field). d: Paraffin section photograph of mouse solid tumor (group treated
with 3-BP and TAM) showing the VEGF expression in some tumor cells (1/5 of the field)
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As the tumor cells proliferate, they are subjected to
hypoxia and undergo biological changes to adapt them-
selves to the hypoxic conditions. HIF-1α mediates many
of the changes, [43] which regulate many genes in glyco-
lytic pathway as hexokinase-2 (HK2) which plays a key
step in glycolysis and angiogenesis as (VEGF) [44]. HIF-
1α has been reported to be over expressed in various
malignant tumors and cancer cell lines [45]. In our study
TAM, 3BP as well as their combination inhibited the ex-
pression and the protein content of HIF-1 α with con-
comitant inhibition of HK and VEGF. However, the
expression levels of both HIF-1 α and HK of the com-
bined treatment in both cell lines showed synergistic ef-
fect which did not appear in the protein level carried out
by Western blotting. Such difference between mRNA ex-
pression and protein level may be due to several bio-
logical and methodological constraints that play a role
when comparing mRNA to protein levels [46]. The most
prominently influences the correlation between mRNA
and protein are the translation efficiency or protein half-
life. Individual protein half-lives range from several sec-
onds to tens of hours [47], a more than 1000-fold range.
Hence protein turnover is probably influencing the cor-
relation between mRNA and protein abundances to a
greater degree. Minor effects are attributed translation
initiation, start codon, stop codon and stop codon con-
text [48] and [49]. HIF-1α plays an important role in
tumor angiogenesis and high levels of HIF-1 α can pre-
dict an early relapse and metastatic disease [50]. Add-
itionally, HIF-1α overexpression is associated with
increased VEGF expression in many different types of
cancer such as; breast cancer, colon cancer and hepato-
cellular carcinoma [51]. However, the role of estrogens
and tamoxifen and in the clinic and HIF-1 α modulation
in breast cancer is unclear [52]. 3-BP was reported to
decrease the level of HIF-1 α [53] and covalently binds
to HK-2, causing its dissociation from VDAC [31]. 3BP
causes cancer cell death by rapid depletion of ATP and
suppresses tumor growth in animal model [54]. The
combined treatment produced significant decrease in
VEGF compared to either drug alone, the effect was syn-
ergistic in MCF7, while it was additive in T47D. This
difference in drug interaction between the two types
could be attributed to the aggressive nature of T47D
compared to MCF7. According to their biological func-
tions, the proteins involved in cell growth stimulation,
anti-apoptosis mechanisms and carcinogenesis are more
strongly expressed in T47D than in MCF7 [55]. More-
over, in vivo the expression level of VEGF was decreased
in mice treated combination regimen significantly com-
pared to TAM or 3-BP treated groups.
Metalloproteinase degrade extracellular matrix compo-
nents enabling tumor cell invasion and metastasis. It
was found that estradiol and TAM regulate MMP-2,
MMP-9 and extracellular endostatin in ER + PR + human
breast cancer cells and in vivo [56, 57]. A significant in-
crease of intracellular and secreted protein levels upon
TAM exposure whereas, estradiol induced a significant
decrease [56]. The authors suggested a possible role of
MMP in regulation the bioavailability of a variety of bio-
logically active molecules such as anti-angiogenic frag-
ments, which may be beneficial for the host [56, 57].
Surprisingly in this study, 3-BP caused a sharp decline in
the MMPs in the two breast cancer cell lines, contrary
to TAM which caused increased levels of both enzymes.
However, the combination regimen succeeded to lower
the increased effect of TAM by all tested techniques
(Fig. 7a-h) with antagonistic interaction. Therefore TAM
and 3BP the ability to modulate MMP-2/MMP-9 activity
and VEGF levels in human breast cancer in vitro.
Conclusion
3-BP is a promising antitumor, it improved antitumor ef-
fect of TAM on breast cancer cell lines and in mice
bearing-Ehrlish carcinoma. The combination regimen
increases the antitumor effect via activation of apoptotic
machinery, decreases angiogenesis markers HIF, HK2
and VEGF. Moreover 3BP modulates MMPs 2 and 9
which makes its combination with TAM promising treat-
ment to be applied clinically.
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